Top

Published in:

01-01-2015

Serum Free Indoxyl Sulfate Associated with In-stent Restenosis After Coronary Artery Stentings

Authors: Ming-Lung Tsai, I-Chang Hsieh, Cheng-Chieh Hung, Chun-Chi Chen

Published in: Cardiovascular Toxicology | Issue 1/2015

Abstract

Uremic toxins, including P-cresyl sulfate (PCS) and indoxyl sulfate (IS), have been found to participate in the process of atherosclerosis and patient mortality. We aim to discover if uremic toxins are related to in-stent restenosis in patients with coronary artery disease after stent implantation. We enrolled 214 patients who received coronary angioplasty with stenting and follow-up angiography between November 1995 and June 2011 with a total of 293 lesions divided into bare metal stent (BMS) or drug-eluting stent (DES) groups. Patients’ basic information and total and free form IS and PCS were used to correlate with the late loss (LL) and loss index (LI). Significantly higher LL and LI in the BMS group compared with the DES group (1.10 vs. 0.45 mm, p < 0.001, and 0.46 vs. 0.19, p < 0.001, respectively). The unadjusted correlation revealed a positive relationship between log-normalized free IS and LL, LI in the DES group (p = 0.001). After adjustment for multiple variables, the log-normalized free IS still presented as an independent predictor for the LL and LI (p = 0.012 and p = 0.031). Free IS is an independent predictor for coronary restenosis in patients receiving DES implantations. However, among patients undergoing BMS stentings, uremic toxin is not a predictor of the intracoronary restenosis.

Sarnak, M. J., Levey, A. S., Schoolwerth, A. C., Coresh, J., Culleton, B., Hamm, L. L., et al. (2003). Kidney disease as a risk factor for development of cardiovascular disease: A statement from the American heart association councils on kidney in cardiovascular disease, high blood pressure research, clinical cardiology, and epidemiology and prevention. Circulation, 108, 2154–2169.CrossRefPubMed

Brunet, P., Gondouin, B., Duval-Sabatier, A., Dou, L., Cerini, C., Dignat-George, F., et al. (2011). Does uremia cause vascular dysfunction? Kidney and blood pressure research., 34, 284–290.CrossRefPubMed

Schiffer, E., Liabeuf, S., Lacroix, C., Temmar, M., Renard, C., Monsarrat, B., et al. (2011). Markers of vascular disease in plasma from patients with chronic kidney disease identified by proteomic analysis. Journal of Hypertension, 29, 783–790.CrossRefPubMed

Barreto, F. C., Barreto, D. V., Liabeuf, S., Meert, N., Glorieux, G., Temmar, M., et al. (2009). Serum indoxyl sulfate is associated with vascular disease and mortality in chronic kidney disease patients. Clinical journal of the American Society of Nephrology : CJASN., 4, 1551–1558.CrossRefPubMedCentralPubMed

Chiu, C. A., Lu, L. F., Yu, T. H., Hung, W. C., Chung, F. M., Tsai, I. T., et al. (2010). Increased levels of total P-Cresylsulphate and indoxyl sulphate are associated with coronary artery disease in patients with diabetic nephropathy. The review of diabetic studies : RDS., 7, 275–284.CrossRefPubMedCentralPubMed

Niwa, T. (2010). Indoxyl sulfate is a nephro-vascular toxin. Journal of renal nutrition : the official journal of the Council on Renal Nutrition of the National Kidney Foundation., 20, S2–S6.CrossRef

Wang, C. P., Lu, L. F., Yu, T. H., Hung, W. C., Chiu, C. A., Chung, F. M., et al. (2010). Serum levels of total p-cresylsulphate are associated with angiographic coronary atherosclerosis severity in stable angina patients with early stage of renal failure. Atherosclerosis., 211, 579–583.CrossRefPubMed

Fujii, H., Nakai, K., & Fukagawa, M. (2011). Role of oxidative stress and indoxyl sulfate in progression of cardiovascular disease in chronic kidney disease. Therapeutic Apheresis and Dialysis, 15, 125–128.CrossRefPubMed

Jourde-Chiche, N., Dou, L., Cerini, C., Dignat-George, F., & Brunet, P. (2011). Vascular incompetence in dialysis patients–protein-bound uremic toxins and endothelial dysfunction. Seminars in Dialysis, 24, 327–337.CrossRefPubMed

10.

Niwa, T. (2011). Role of indoxyl sulfate in the progression of chronic kidney disease and cardiovascular disease: experimental and clinical effects of oral sorbent AST-120. Therapeutic Apheresis and Dialysis, 15, 120–124.CrossRefPubMed

11.

Wu, I. W., Hsu, K. H., Lee, C. C., Sun, C. Y., Hsu, H. J., Tsai, C. J., et al. (2011). p-Cresyl sulphate and indoxyl sulphate predict progression of chronic kidney disease. Nephrology, Dialysis, Transplantation., 26, 938–947.CrossRefPubMedCentralPubMed

12.

Sato, B., Yoshikawa, D., Ishii, H., Kikuchi, R., Arima, T., Takeshita, K., et al. (2013). Indoxyl sulfate, a uremic toxin, and carotid intima-media thickness in patients with coronary artery disease. International Journal of Cardiology, 163, 214–216.CrossRefPubMed

13.

de Loor, H., Bammens, B., Evenepoel, P., De Preter, V., & Verbeke, K. (2005). Gas chromatographic-mass spectrometric analysis for measurement of p-cresol and its conjugated metabolites in uremic and normal serum. Clinical Chemistry, 51, 1535–1538.CrossRefPubMed

14.

Niwa, T., & Ise, M. (1994). Indoxyl sulfate, a circulating uremic toxin, stimulates the progression of glomerular sclerosis. The Journal of Laboratory and Clinical Medicine, 124, 96–104.PubMed

15.

Dou, L., Jourde-Chiche, N., Faure, V., Cerini, C., Berland, Y., Dignat-George, F., et al. (2007). The uremic solute indoxyl sulfate induces oxidative stress in endothelial cells. Journal of Thrombosis and Haemostasis: JTH., 5, 1302–1308.CrossRefPubMed

16.

Dou, L., Bertrand, E., Cerini, C., Faure, V., Sampol, J., Vanholder, R., et al. (2004). The uremic solutes p-cresol and indoxyl sulfate inhibit endothelial proliferation and wound repair. Kidney International, 65, 442–451.CrossRefPubMed

17.

Yamamoto, H., Tsuruoka, S., Ioka, T., Ando, H., Ito, C., Akimoto, T., et al. (2006). Indoxyl sulfate stimulates proliferation of rat vascular smooth muscle cells. Kidney International, 69, 1780–1785.CrossRefPubMed

18.

Schepers, E., Meert, N., Glorieux, G., Goeman, J., Van der Eycken, J., & Vanholder, R. (2007). P-cresylsulphate, the main in vivo metabolite of p-cresol, activates leucocyte free radical production. Nephrology, Dialysis, Transplantation, 22, 592–596.CrossRefPubMed

19.

Meijers, B. K., Bammens, B., De Moor, B., Verbeke, K., Vanrenterghem, Y., & Evenepoel, P. (2008). Free p-cresol is associated with cardiovascular disease in hemodialysis patients. Kidney International, 73, 1174–1180.CrossRefPubMed

20.

Abbott, J. D., Voss, M. R., Nakamura, M., Cohen, H. A., Selzer, F., Kip, K. E., et al. (2007). Unrestricted use of drug-eluting stents compared with bare-metal stents in routine clinical practice: findings from the National Heart, Lung, and Blood Institute Dynamic Registry. Journal of the American College of Cardiology, 50, 2029–2036.CrossRefPubMed

21.

Stettler, C., Wandel, S., Allemann, S., Kastrati, A., Morice, M. C., Schomig, A., et al. (2007). Outcomes associated with drug-eluting and bare-metal stents: a collaborative network meta-analysis. Lancet, 370, 937–948.CrossRefPubMed

22.

Fischman, D. L., Leon, M. B., Baim, D. S., Schatz, R. A., Savage, M. P., Penn, I., et al. (1994). A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. Stent Restenosis Study Investigators. The New England Journal of Medicine., 331, 496–501.CrossRefPubMed

23.

Serruys, P. W., de Jaegere, P., Kiemeneij, F., Macaya, C., Rutsch, W., Heyndrickx, G., et al. (1994). A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. Benestent study group. The New England Journal of Medicine., 331, 489–495.CrossRefPubMed

24.

Hoffmann, R., Mintz, G. S., Dussaillant, G. R., Popma, J. J., Pichard, A. D., Satler, L. F., et al. (1996). Patterns and mechanisms of in-stent restenosis. A serial intravascular ultrasound study. Circulation, 94, 1247–1254.CrossRefPubMed

25.

Kearney, M., Pieczek, A., Haley, L., Losordo, D. W., Andres, V., Schainfeld, R., et al. (1997). Histopathology of in-stent restenosis in patients with peripheral artery disease. Circulation, 95, 1998–2002.CrossRefPubMed

26.

Kornowski, R., Hong, M. K., Tio, F. O., Bramwell, O., Wu, H., & Leon, M. B. (1998). In-stent restenosis: Contributions of inflammatory responses and arterial injury to neointimal hyperplasia. Journal of the American College of Cardiology, 31, 224–230.CrossRefPubMed

27.

Komatsu, R., Ueda, M., Naruko, T., Kojima, A., & Becker, A. E. (1998). Neointimal tissue response at sites of coronary stenting in humans: macroscopic, histological, and immunohistochemical analyses. Circulation, 98, 224–233.CrossRefPubMed

28.

Hill RA, Boland A, Dickson R, Dundar Y, Haycox A, McLeod C, et al. Drug-eluting stents: a systematic review and economic evaluation. Health Technol Assess. 2007;11:iii, xi-221.

29.

Lemos, P. A., Hoye, A., Goedhart, D., Arampatzis, C. A., Saia, F., van der Giessen, W. J., et al. (2004). Clinical, angiographic, and procedural predictors of angiographic restenosis after sirolimus-eluting stent implantation in complex patients: an evaluation from the rapamycin-eluting stent evaluated at Rotterdam cardiology hospital (RESEARCH) study. Circulation, 109, 1366–1370.CrossRefPubMed

30.

Dangas, G. D., Claessen, B. E., Caixeta, A., Sanidas, E. A., Mintz, G. S., & Mehran, R. (2010). In-stent restenosis in the drug-eluting stent era. Journal of the American College of Cardiology, 56, 1897–1907.CrossRefPubMed

31.

Ota, T., Umeda, H., Yokota, S., Miyata, S., Takamura, A., Sugino, S., et al. (2009). Relationship between severity of renal impairment and 2-year outcomes after sirolimus-eluting stent implantation. American Heart Journal, 158, 92–98.CrossRefPubMed

32.

Wu, I. W., Hsu, K. H., Hsu, H. J., Lee, C. C., Sun, C. Y., Tsai, C. J., et al. (2012). Serum free p-cresyl sulfate levels predict cardiovascular and all-cause mortality in elderly hemodialysis patients–a prospective cohort study. Nephrology, Dialysis, Transplantation, 27, 1169–1175.CrossRefPubMed

33.

Meijers, B. K., Van Kerckhoven, S., Verbeke, K., Dehaen, W., Vanrenterghem, Y., Hoylaerts, M. F., et al. (2009). The uremic retention solute p-cresyl sulfate and markers of endothelial damage. American Journal of Kidney Diseases, 54, 891–901.CrossRefPubMed

34.

Lin, C. J., Chuang, C. K., Jayakumar, T., Liu, H. L., Pan, C. F., Wang, T. J., et al. (2013). Serum p-cresyl sulfate predicts cardiovascular disease and mortality in elderly hemodialysis patients. Archives of Medical Science: AMS., 9, 662–668.CrossRefPubMedCentralPubMed

35.

Adijiang, A., Goto, S., Uramoto, S., Nishijima, F., & Niwa, T. (2008). Indoxyl sulphate promotes aortic calcification with expression of osteoblast-specific proteins in hypertensive rats. Nephrology, Dialysis, Transplantation, 23, 1892–1901.CrossRefPubMed

36.

Niwa, T. (2010). Uremic toxicity of indoxyl sulfate. Nagoya Journal of Medical Science, 72, 1–11.PubMed

Title: Serum Free Indoxyl Sulfate Associated with In-stent Restenosis After Coronary Artery Stentings
Authors: Ming-Lung Tsai
I-Chang Hsieh
Cheng-Chieh Hung
Chun-Chi Chen
Publication date: 01-01-2015
Publisher: Springer US
Published in: Cardiovascular Toxicology / Issue 1/2015
Print ISSN: 1530-7905
Electronic ISSN: 1559-0259
DOI: https://doi.org/10.1007/s12012-014-9270-2

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Serum Free Indoxyl Sulfate Associated with In-stent Restenosis After Coronary Artery Stentings

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2015

Cardiovascular Effects of Phaleria macrocarpa Extracts Combined with Mainstay FAC Regimen for Breast Cancer

Cardiogenic shock due to acute tramadol intoxication

Role of Autonomic Reflex Arcs in Cardiovascular Responses to Air Pollution Exposure

Lagerstroemia speciosa L. Attenuates Apoptosis in Isoproterenol-Induced Cardiotoxic Mice by Inhibiting Oxidative Stress: Possible Role of Nrf2/HO-1

Expression of Sarcomeric Tropomyosin in Striated Muscles in Axolotl Treated with Shz-1, a Small Cardiogenic Molecule

Modified High-Density Lipoproteins by Artificial Sweetener, Aspartame, and Saccharin, Showed Loss of Anti-atherosclerotic Activity and Toxicity in Zebrafish

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page